Table 3.
Posaconazole
| Overall (n = 100) | |||
|---|---|---|---|
| Drug concentration (μg/ml) (Median [IQR]) | 1.26 (0.50–1.91) | ||
| Comparison | Therapeutic drug level (n = 69) | Non-therapeutic drug level (n = 31) | p |
| PK parameters | |||
| Drug concentration (μg/ml) (median [IQR]) | 1.61 (1.17–2.30) | 0.19 (0.15–0.48) | <0.01 |
| Total daily dose (mg) (median [IQR]) | 300 (300–400) | 800 (600–1200) | <0.01 |
| mg/kg/dose (median [IQR]) | 4.03 (3.3–4.9) | 4.08 (2.5–5.5) | 0.75 |
| mg/kg/day (median [IQR]) | 4.68 (3.8–7.5) | 9.67 (5.5–13.9) | <0.01 |
| Weight (median [IQR]) | 72 (55.3–80.0) | 77 (64.0–88.6) | 0.05 |
| Concomitant interacting medication | 13 (19) | 8 (26) | 0.44 |
| PK parameters—initial dose only | (n = 21) | (n = 17) | |
| mg/kg/dose (median [IQR]) | 4.16 (3.6–5.2) | 4.38 (2.5–5.4) | 0.54 |
| mg/kg/day (median [IQR]) | 5.67 (4.0–9.6) | 10.49 (5.4–14.4) | 0.04 |
| Weight (median [IQR]) | 74 (59.0–84.5) | 77 (64.0–87.7) | 0.36 |
| Patient characteristics | |||
| Critically ill | 34 (49) | 16 (52) | 1.00 |
| Solid organ transplant recipients | 17 (25) | 4 (13) | 0.29 |
| Bone marrow transplant recipients | 14 (20) | 12 (39) | 0.08 |
| Cystic fibrosis | 1 (1) | 1 (3) | 0.53 |
| Immunocompromiseda | 41 (59) | 25 (81) | 0.04 |
| Outcomes | |||
| Length of stay (days) (median [IQR]) | 27 (17–48) | 43 (36-76) | <0.01 |
| Treatment failure | 13 (18) | 9 (30) | 0.30 |
| Comparison by patient | Therapeutic mean drug level (n = 22) | Non-therapeutic mean drug level (n = 16) | |
|---|---|---|---|
| Outcomes | |||
| Survive to hospital discharge (n = 38) | 14 (64) | 12 (75) | 0.50 |
| Treatment failure | 4 (18) | 3 (18) | 1.00 |
| Length of stay (days) (median [IQR]) | 23 (8–36) | 40 (35–57) | <0.01 |
Data are presented as n (%) or median (interquartile range)
IQR interquartile range
aNeutropenia, allogeneic stem cell transplant, solid organ transplant, prolonged use of corticosteroids, or T-cell immunosuppressive therapy